Bayh-Dole Reform and the Progress of Biomedicine
By Arti Rai, Rebecca Eisenberg
Allowing universities to patent the results of government-sponsored research sometimes works against the public interest
This Article From Issue
January-February 2003
Volume 91, Number 1
Page 52
DOI: 10.1511/2003.11.52
Although the development of pharmaceutical compounds has long been a commercial enterprise, the broader field of biomedical research has enjoyed a very different tradition, one that allows the free sharing of scientific knowledge. But the culture of open science has eroded considerably over the past quarter-century.
BioReliance Corporation
American Scientist Comments and Discussion
To discuss our articles or comment on them, please share them and tag American Scientist on social media platforms. Here are links to our profiles on Twitter, Facebook, and LinkedIn.
If we re-share your post, we will moderate comments/discussion following our comments policy.